2019 Novel Coronavirus (2019-nCoV)

As of March 23, IDT has shipped primer and probe kits sufficient to enable more than 10 million tests to be conducted in the US pursuant to the CDC EUA testing protocol.

IDT has received inquiries from researchers from around the world who are interested in rapidly obtaining assays and developing vaccines targeting the novel coronavirus (2019-nCoV/SARS-CoV-2) identified in Wuhan, China. Supporting these efforts, the CDC and the Chinese government have sequenced and submitted the coronavirus genome to the US NCBI GenBank® database [1]. With our worldwide manufacturing capabilities, IDT is uniquely able to provide robust qPCR assays while avoiding contamination issues from synthesis of controls and related gene fragments. 

Virus detection

The US Centers for Disease Control and Prevention (CDC) has designed RT-PCR assays and published a protocol for the detection of the 2019-nCoV. IDT provides primers and probes for these CDC assays for the identification of virus. The primers and probes are manufactured at IDT under ISO 13485:2016 conditions and are available for research use only (RUO). The kits include primers and 5’ FAM / 3’ Black Hole Quencher® (BHQ) probes. 2019-nCoV controls* are available separately.

On February 4th, 2020, the FDA issued an Emergency Use Authorization (EUA) to the CDC to expand the use of assays to positively identify the coronavirus [2,3].

 

2019-nCoV CDC qPCR Probe Assay

Updated March 26, 2020

The CDC has quality controlled and authorized primers and probes for the N1, N2 and RP assays from following batches to be sold under the CDC EUA (dated February 29, 2020, and as amended):

0000500383, 0000504847, 0000505594, 0000505969, 0000507295, 0000507509, 0000508150, 0000508785, 0000509402, and 0000510344

The CDC did not QC the N3 assays, and the N3 assay is not part of the authorized kits.   The FDA approved the CDC’s amended protocol that excludes the N3 Assay on March 15, 2020.    All kits from all future batches of IDT primers and probes will not include the N3 assay.

 


Ordering assays through our dedicated coronavirus channels ensures:

  • Fast shipping (same or next business day)
  • ISO 13485:2016 standards of production
  • CDC designed rRT-PCR Primers and Probes  
  • Preferred pricing

 

2019-nCoV RUO Plasmid Controls


Ordering controls through our dedicated coronavirus channels ensures:

  • Fast shipping (1–2 business days)
  • ISO 9001:2015 standards of production
  • Sequence verified  
  • Preferred pricing

* The IDT controls have not been designed, tested, validated by CDC, nor are they in any way endorsed by the CDC or any other public health agency. These controls were independently designed by IDT against the entire nucleocapsid gene of SARS, MERS, and 2019-nCOV. These controls are offered as a convenience to our customers. Controls should be validated by the end-user if used for the interpretation of test results.

Don’t see what you need for your nCoV experiments?

We can accommodate custom requests.

Contact us

Vaccine development

Advances in gene synthesis mean that subunit vaccines can be developed quickly from one or more antigen-presenting viral genes or peptide sequences, which circumvents the need for scientists to handle live and potentially dangerous pathogens, and eliminates the time needed to clone DNA fragments.

Use IDT double-stranded DNA fragments to create synthetic proteins designed as safe reagents for vaccine research. IDT offers 3 convenient options: linear gBlocks Gene Fragments, eBlocks Gene Fragments, or Custom Genes cloned into vectors. These are available in varying lengths and synthesis scales. Start your order, and we will help you choose the format that best fits your needs.

Ready to order?  Place your order using: https://www.idtdna.com/pages/products/genes-and-gene-fragments.

Looking for fast and safer reagents for your vaccine research?

We can help you choose the best format for your antigen target screening.

Sign Up

CDC Information for laboratories

Access the CDC’s latest laboratory guidance for 2019-nCoV RT-PCR assays.

Information for laboratories

Media Information

IDT is honored to be the first company in the nation to have our primer and probe kits approved by the CDC for use as a key component of the CDC EUA testing protocol for the diagnosis and detection of COVID-19. We are proud to have rapidly achieved large-scale manufacturing of this key component which enables testing of millions of Americans for COVID-19.

For media inquiries about IDT’s role in the fight against COVID-19, please contact:

IDT Public Relations, idtpr@idtdna.com
Anna Blyth, ablyth@apcoworldwide.com
Iris Shaffer, ishaffer@apcoworldwide.com

References

  1. (2020) 2019 Novel Coronavirus (2019-nCoV), Wuhan, China. [Online] US Centers for Disease Control and Prevention. [Accessed 28 Jan 2020].
  2. (2020) Emergency use authorization. [Online] US Centers for Disease Control and Prevention. [Accessed 28 Jan 2020].
  3. (2020) CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel . [Online] US Centers for Disease Control and Prevention. [Accessed 3 Mar 2020].
Your Advocate for the Genomics Age